The most popular growth hormone secretagogue in the peptide community—and the uncomfortable truth about where its evidence actually comes from

If you have spent any time reading about peptide protocols for growth hormone optimization, you have encountered CJC-1295. It is half of the most commonly prescribed combination in anti-aging clinics (CJC-1295 + ipamorelin) and arguably the most widely used GHRH analog in the self-experimentation community. It is also a compound whose popularity has almost entirely outrun its evidence.

The disconnect begins with the name. When researchers published the landmark studies on "CJC-1295"—the Teichman 2006 dose-escalation trial and the Ionescu 2006 GH profiling study—they were studying a compound conjugated with a Drug Affinity Complex that covalently binds to serum albumin, extending its half-life to 5.8–8.1 days. The product sold as "CJC-1295 no DAC" or "Mod GRF 1-29" at peptide vendors and compounding pharmacies does not have this modification. It has a half-life of approximately 30 minutes. These are pharmacologically different compounds sharing a name.

This is not a trivial technicality. A compound with a week-long half-life produces a fundamentally different GH profile than one that clears in 30 minutes. The clinical data from the DAC version cannot be directly applied to the no-DAC version any more than sustained-release morphine data can be applied to immediate-release morphine. The mechanism is the same; the pharmacokinetics are not; and pharmacokinetics determine what actually happens in the body.

What the no-DAC version does have: a well-characterized mechanism (GHRH receptor agonism, proven across decades of research with sermorelin and native GHRH), four amino acid substitutions that demonstrably improve enzymatic stability, and a short half-life that preserves pulsatile GH release—arguably a pharmacological advantage over the DAC version. What it lacks: a single published, controlled human clinical trial.

Quick Facts: CJC-1295 without DAC at a Glance

What Is CJC-1295 (No DAC)?

Pronunciation: see-jay-see-twelve-ninety-five (no dack) / mod-jee-are-eff-one-twenty-nine (also known as Modified GRF(1-29), Mod GRF 1-29, Tetrasubstituted GRF(1-29))

Every cell in your pituitary gland that stores growth hormone has a lock on its surface called the GHRH receptor. The key that opens this lock is a 44-amino acid peptide released by your hypothalamus—growth hormone-releasing hormone. Sermorelin, the first pharmaceutical GHRH analog, copies the first 29 amino acids of that key. CJC-1295 (no DAC) starts with the same 29 amino acids and then makes four strategic changes—swapping in amino acids that resist enzymatic breakdown—tripling the time the key stays in the lock before being destroyed.

That is the entire innovation. Not a new mechanism. Not a new receptor. A more durable version of the same signal your body already sends. The native GHRH(1-29) fragment lasts about 10 minutes in the bloodstream before DPP-IV enzymes chew it apart. Sermorelin lasts about 10–20 minutes. CJC-1295 (no DAC), with its four protective substitutions, survives for approximately 30 minutes—long enough to produce a stronger, more sustained GH pulse while still clearing fast enough to preserve pulsatile physiology.

The confusion that surrounds this compound begins and ends with its name. "CJC-1295" was the designation used by ConjuChem Biotechnologies for their Drug Affinity Complex–conjugated version—a fundamentally different product that binds to albumin in the bloodstream and lingers for nearly a week. The no-DAC version borrowed the CJC-1295 name and appended "without DAC" or was relabeled "Mod GRF 1-29" to distinguish it. In practice, the distinction is often lost, and the published human data for the DAC version is routinely attributed to the no-DAC product.

Origins and Discovery

The foundation for CJC-1295 lies in the structure-activity research that followed the isolation of GHRH in the early 1980s. Once the 44-amino acid sequence was known and the biologically active (1-29) fragment identified, medicinal chemists began systematically substituting amino acids to improve metabolic stability.

The four substitutions that define tetrasubstituted GRF(1-29) were identified through academic research aimed at preventing DPP-IV cleavage. DPP-IV (dipeptidyl peptidase IV) is a serine protease that cleaves the first two amino acids from GHRH, inactivating it within minutes. The D-Ala² substitution at position 2 directly blocks this cleavage site. The remaining three substitutions (Gln⁸, Ala¹⁵, Nle²⁷) further improve stability and reduce immunogenicity.

ConjuChem Biotechnologies, a Montreal-based company, took the tetrasubstituted base peptide and added the Drug Affinity Complex—a maleimido linker enabling covalent binding to serum albumin. This transformed the pharmacokinetics from ~30 minutes to ~6–8 days. ConjuChem conducted the human clinical trials under the "CJC-1295" designation and was developing the compound for growth hormone deficiency, HIV wasting, and visceral obesity.

A patient death during the HIV visceral obesity trial—attributed to pre-existing coronary artery disease—and subsequent corporate financial difficulties led ConjuChem to bankruptcy in 2010. Patrick Soon-Shiong acquired the company's assets in 2010–2011 but did not resume CJC-1295 development. No new clinical data has been published for either version since 2006.

The no-DAC version entered the peptide vendor marketplace without pharmaceutical development, clinical trials, or regulatory review. It became the de facto GHRH analog of choice in the community because it preserves pulsatile GH release (unlike the DAC version's sustained profile) and pairs logically with GHS-R1a agonists.

Mechanism of Action

CJC-1295 (no DAC) binds the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotroph cells—the same receptor bound by native GHRH and sermorelin. GHRHR signals through Gs → adenylyl cyclase → cAMP → protein kinase A (PKA) → calcium mobilization → GH granule exocytosis.

The four amino acid substitutions do not alter the receptor interaction or the signaling cascade. They serve a single purpose: enzymatic resistance. DPP-IV cleaves native GHRH(1-29) at the Ala² position within minutes. The D-Ala² substitution creates a non-natural stereochemistry that DPP-IV cannot recognize, blocking the primary degradation pathway. The remaining substitutions (Gln⁸, Ala¹⁵, Nle²⁷) reduce susceptibility to other circulating proteases and improve chemical stability.

The result: A GHRH analog that produces a GH pulse approximately 3× longer than native GHRH or sermorelin (~30 minutes vs. ~10 minutes), but still within the range of physiological pulsatile dynamics. Somatostatin negative feedback remains fully engaged—GH levels are constrained by the same self-limiting ceiling that governs natural GHRH-driven secretion.

Dual-pathway synergy with GHS-R1a agonists: GHRHR (Gs/cAMP) and GHS-R1a (Gq/11/PLC/IP3/Ca²⁺) converge on the same somatotroph cell but through independent signaling cascades. Co-activation produces GH release exceeding what either pathway achieves alone—a pharmacological synergy demonstrated with GHRH + GHRP combinations in controlled settings. This is the mechanistic rationale for the CJC-1295 (no DAC) + ipamorelin combination stack.

What CJC-1295 (no DAC) does NOT do: It does not bind GHS-R1a (the ghrelin receptor). It does not stimulate appetite. It does not elevate cortisol or ACTH (at GHRH-receptor-stimulating doses). It does not bind albumin (that is the DAC version's function). It does not produce sustained GH elevation.

Key Research Areas and Studies

The GHRH Receptor Pathway — Validated by Other Compounds

The mechanism CJC-1295 (no DAC) relies on—GHRHR agonism for GH release—is among the best-validated pathways in endocrinology. Sermorelin (FDA-approved), native GHRH (the endogenous ligand), and tesamorelin (currently FDA-approved for HIV lipodystrophy) all act through this receptor. The pharmacological principle is not in question. The question is whether this specific formulation delivers on that principle in humans—and that question has not been answered by published clinical data.

Preclinical Characterization (Jetté et al. 2005)

Jetté et al. (PMID 15817669) characterized the tetrasubstituted GRF(1-29) in rats. The base peptide (without DAC) showed a 4-fold increase in GH area under the curve compared to native GRF(1-29). With the DAC conjugation, immunoreactive species persisted >72 hours. This study establishes the pharmacokinetic advantage of the substitutions but is animal data—half-life and bioavailability do not directly translate to humans.

The DAC-Version Human Trials (NOT Directly Applicable)

Teichman et al. 2006 (PMID 16352683) conducted a double-blind, placebo-controlled ascending-dose trial in healthy adults. Half-life was 5.8–8.1 days. GH increased 2–10-fold for 6+ days. IGF-1 increased 1.5–3-fold for 9–11 days. Well tolerated at 30–60 µg/kg.

Ionescu & Frohman 2006 (PMID 17018654) showed that despite continuous GHS-R stimulation from the long-acting DAC-conjugated compound, pulsatile GH secretion was preserved. This is an important finding for the DAC version—but its relevance to the no-DAC version (which is already pulsatile by virtue of its short half-life) is limited.

These studies are important context. They are not evidence for the no-DAC product.

The Combination Protocol — Mechanistic Rationale Without Clinical Proof

The CJC-1295 (no DAC) + ipamorelin combination is based on dual-pathway synergy: GHRHR + GHS-R1a co-activation. Studies with native GHRH + GHRP combinations (not specifically CJC-1295 no DAC + ipamorelin) have demonstrated synergistic GH release in controlled settings. The principle is well-established in the GHRH + GHRP literature. The specific combination product has never been tested in a published human clinical trial.

The Critical Distinction: DAC vs. No DAC

This is the section that justifies this compound's place on Peptidings and defines its editorial identity. The distinction between CJC-1295 with DAC and CJC-1295 without DAC is not a footnote—it is the entire story.

What DAC is: Drug Affinity Complex. A reactive chemical group (maleimido moiety) attached to the peptide's C-terminus that forms a covalent bond with a cysteine-34 residue on serum albumin after injection. This binding extends the compound's effective half-life from ~30 minutes to 5.8–8.1 days—a 200-fold increase.

Why this matters for readers: When a website, vendor, or practitioner cites "the CJC-1295 study showing 2–10-fold GH increase for 6+ days," they are citing data from a compound that does not exist in the no-DAC product. The 6-day GH elevation is a function of the DAC modification—without it, the peptide clears in 30 minutes. Citing DAC-version data to support no-DAC product claims is like citing extended-release data to justify immediate-release dosing recommendations.

The ironic advantage of no DAC: The short half-life that limits the no-DAC version's evidence borrowing may actually be its pharmacological advantage. Pulsatile GH release more closely mimics natural physiology than sustained elevation. The pituitary's somatotroph cells respond differently to pulsed vs. continuous GHRH stimulation. For users seeking physiological GH optimization rather than maximal GH elevation, the no-DAC version's pulsatile profile may be preferable—but this has not been tested in a head-to-head human trial.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Direct Human Evidence for CJC-1295 (No DAC)

No published, peer-reviewed clinical trial has specifically studied CJC-1295 without DAC (Mod GRF 1-29) in human subjects. This is not an oversight—the compound was never developed as a pharmaceutical product. It entered the market through the peptide vendor and compounding pharmacy ecosystem without clinical development.

Indirect Evidence: The DAC-Version Trials

Teichman et al. 2006 — The Dose-Escalation Study (DAC VERSION) Design: Randomized, double-blind, placebo-controlled, ascending dose. N: Healthy adults, ages 21–61. Compound: CJC-1295 WITH DAC. Half-life: 5.8–8.1 days. Key findings: GH increased 2–10-fold for 6+ days per dose. IGF-1 increased 1.5–3-fold for 9–11 days. Cumulative effect with repeated weekly dosing. Well tolerated at 30–60 µg/kg. Relevance to no-DAC: Demonstrates that the base GHRH(1-29) sequence activates GHRHR in humans. Does NOT demonstrate the pharmacokinetics, dosing, or magnitude of effect for the no-DAC version. PMID: 16352683

Ionescu & Frohman 2006 — GH Pulsatility Study (DAC VERSION) Design: Clinical trial with overnight frequent GH sampling. N: ~8–12 healthy males, 20–40 years. Compound: CJC-1295 WITH DAC (confirmed by description of permanent albumin binding). Key findings: Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation. Trough GH increased 7.5-fold. Mean GH increased 46%. IGF-1 elevated 45%. Relevance to no-DAC: The finding that pulsatility persists even with sustained GHRH receptor stimulation is interesting but not directly relevant—the no-DAC version is already pulsatile by virtue of its short half-life. PMID: 17018654

Indirect Evidence: The Broader GHRH Pathway

Sermorelin's FDA-approved clinical data (Geref International Study Group 1996, Khorram 1997, Corpas 1992) demonstrates that GHRHR agonism reliably stimulates GH and IGF-1 in humans. CJC-1295 (no DAC) activates the same receptor with the same signaling cascade. The inference that it produces similar effects is pharmacologically reasonable—but unproven.

What Would Need to Happen

For CJC-1295 (no DAC) to reach Tier 2 evidence: at minimum, a controlled human study demonstrating GH stimulation with the specific compound (not the DAC version), characterizing its pharmacokinetics in humans, and measuring clinical outcomes. For the combination protocol: a controlled trial testing CJC-1295 (no DAC) + ipamorelin against either compound alone and placebo.

Safety, Risks, and Limitations

Known Safety Profile (Extrapolated from GHRH Pathway)

CJC-1295 (no DAC) activates the same receptor as sermorelin, which has the most extensive safety record in the cluster (including FDA-approved post-market data). Expected side effects include injection site reactions (pain, redness, swelling), transient facial flushing, and headache—all consistent with GHRH-mediated GH release.

Antibody Formation

The ConjuChem trials (DAC version) documented anti-drug antibody formation in some subjects. Whether the no-DAC version triggers antibody formation at clinically relevant rates is unknown—but it is a standard risk with any exogenous peptide.

Compounding Quality Risk

Same concern as sermorelin: no pharmaceutical-grade product exists. All available CJC-1295 (no DAC) is compounded or vendor-sourced. Potency, purity, and sterility vary by manufacturer. No USP monograph governs the product.

Safety Data Gap

The fundamental safety limitation: no published human safety data exists for this specific compound. The safety profile is inferred from the GHRH receptor pathway (sermorelin) and from the DAC-version trials. This is pharmacologically reasonable but not equivalent to demonstrated safety.

What Is NOT Known

• Human pharmacokinetics (exact half-life, Cmax, Tmax, bioavailability)
• Dose-response relationship in humans
• Long-term safety at any dose
• Drug interactions
• Effects in populations with renal or hepatic impairment
• Safety of the combination with ipamorelin

Legal and Regulatory Status

CJC-1295's regulatory history is a case study in the 2023–2026 FDA peptide landscape:

• 2023–2024: FDA placed CJC-1295 on the Category 2 nomination list, effectively banning its compounding under 503A regulations.
• September 2024: Nominators withdrew, and CJC-1295 was removed from Category 2—restoring the ability of compounding pharmacies to produce it, at least temporarily.
• February 2026: HHS announced intent to lift peptide bans including CJC-1295, signaling a potential return to broader compounding availability.
• Current (April 2026): Regulatory status remains in flux. Availability through compounding pharmacies varies by jurisdiction and individual pharmacy decision.
• WADA: Prohibited under S2. Banned in- and out-of-competition.
• DEA: Not a controlled substance.
• Never FDA-approved. Never submitted for regulatory review. Unlike sermorelin (Tier 1 with historical FDA approval), CJC-1295 has never been evaluated by any regulatory agency.

Research Protocols and Formulation Considerations

CJC-1295 (no DAC) is available as: - Lyophilized powder for reconstitution: Standard format from compounding pharmacies and peptide vendors. Reconstituted with bacteriostatic water. - Multi-dose vials: Typically 2 mg or 5 mg.

Storage: Unreconstituted powder is relatively stable. Reconstituted solution should be refrigerated (2–8°C / 36–46°F) and used within 14–28 days.

The tetrasubstituted modifications improve chemical stability compared to native GHRH(1-29) and sermorelin, but the compound is still a peptide subject to degradation from heat, light, and microbial contamination.

Dosing in Published Research

The following table summarizes dosing protocols for CJC-1295 without DAC as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

No published human dosing data exists for CJC-1295 (no DAC). All dosing protocols currently in use are derived from: 1. Extrapolation from sermorelin dosing (which uses the same receptor) 2. Pharmacokinetic inference from the animal data (Jetté 2005) 3. Community experience and clinical observation

Dosing in Self-Experimentation Communities

Community dosing protocols for CJC-1295 (no DAC) are standardized primarily through anti-aging clinical practice and community consensus, not published research:

• Standard community dose: 100 µg (0.1 mg) per injection, 1–3 times daily
• Combination protocol (with ipamorelin): 100 µg CJC-1295 (no DAC) + 100–200 µg ipamorelin, injected together subcutaneously before bedtime (most common) or split across morning and bedtime doses
• Timing: Before bedtime is the dominant protocol (consistent with GHRH-mediated nocturnal GH pulse amplification). Some protocols add a morning dose.
• Cycle length: 8–12 weeks with 4-week breaks is the most common community pattern. Some anti-aging clinics prescribe continuous use.
• Saturation dose concept: Community consensus suggests that GHRH receptor saturation occurs at approximately 100–200 µg per dose, with diminishing returns beyond that range. This concept is pharmacologically plausible but has not been characterized in human dose-response studies for this compound.

No controlled human trial has validated any community dosing protocol for CJC-1295 (no DAC), either alone or in combination with ipamorelin. The doses used are reasonable extrapolations from GHRH pharmacology but are not evidence-based in the clinical trial sense.

Combination Stacks

Research into CJC-1295 without DAC combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining CJC-1295 without DAC with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

CJC-1295 (no DAC) presents the most striking gap between popularity and evidence of any compound on this site. It is half of the most widely used peptide protocol in the growth hormone secretagogue space—and it has no published human clinical trial data of its own. The human studies cited in its support were conducted with a pharmacologically different compound (the DAC-conjugated version) that has a 200-fold longer half-life.

What CJC-1295 (no DAC) does have: a well-validated mechanism (GHRH receptor agonism, proven across decades of research with sermorelin and native GHRH), four amino acid substitutions that demonstrably improve enzymatic stability, a short half-life that preserves pulsatile GH physiology, and a logical synergy with ghrelin-receptor agonists based on complementary signaling pathways. The pharmacological case is sound. The clinical proof is absent.

This compound's story is a case study in how the peptide community fills evidence gaps with mechanistic reasoning and experiential consensus. The reasoning is often correct—GHRH receptor agonism does stimulate GH release, and dual-pathway stimulation likely is synergistic. But "likely" and "demonstrated" are not the same thing, and the distance between them is what clinical trials are designed to measure.

Verdict Recapitulation

CJC-1295 (no DAC) earns an Eyes Open verdict because the pharmacological rationale is stronger than what Thin Ice compounds offer, but the compound-specific evidence is weaker than what Reasonable Bet requires. The GHRH receptor pathway is validated. The four substitutions are characterized in preclinical work. The combination logic with ipamorelin is pharmacologically sound. But the actual product has never been tested in a published human trial—and the published "CJC-1295" data that surrounds it in vendor marketing and community discussion belongs to a fundamentally different compound. Users should proceed with the understanding that they are relying on mechanistic inference, not clinical proof.

For readers considering CJC-1295 without DAC, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source CJC-1295 without DAC

Further Reading and Resources

If you want to go deeper on CJC-1295 without DAC, the evidence landscape for growth hormone secretagogues peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Growth Hormone Secretagogues Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: CJC-1295 without DAC — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID 16352683 *[DAC VERSION]*
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. PMID 17018654 *[DAC VERSION]*
3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. PMID 15817669

---